You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest General Articles
Popular General Articles
Highly Recommended General Articles
Send a link to this page to your friends and colleagues.
Novo Nordisk has recently filed a patent infringement lawsuit in New Jersey Federal Court against Genentech, Eli Lilly, Pharmacia & Upjohn and Serono corporations. The companies all make and/or sell biosynthetic human growth hormone products that compete with Novo's Norditropin.
This is not the first time Novo has had patent problems. Norditropin was approved by the FDA in May 1995, but due to patent litigation between Novo and Genentech, it was not launched until February 1997.
Novo says its patent is infringed on by Genentech's Nutropin and Nutropin AQ, Lilly's Humatrope, P&U's Genotropin and Serono's Serostim and Saizen products. Lilly is also accused of two additional patent infringements.
Nov 1, 1997
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.